Table 4.

Hazard Ratios for Muscular Events in the Primary Prevention Cohorts Before and After Propensity Score Matching

	Hazard ratio (95% CI)
	Crude	PS-matched
Low-intensity statin therapy
Pravastatin vs simvastatin (ref)
Overall	0.70 (0.56–0.87)	0.86 (0.64–1.16)
Time-specific* (days of follow-up)
1–30	0.41 (0.21–0.80)	0.60 (0.26–1.37)
31–90	0.51 (0.31–0.83)	0.60 (0.32–1.11)
91–180	0.74 (0.48–1.13)	0.97 (0.54–1.74)
181–365	1.02 (0.73–1.44)	1.13 (0.70–1.82)
Moderate- to high-intensity statin therapy
Rosuvastatin vs atorvastatin (ref)
Overall	1.36 (1.11–1.68)	1.17 (0.88–1.56)
Time-specific* (days of follow-up)
1–30	1.44 (0.84–2.46)	1.15 (0.55–2.42)
31–90	1.56 (1.07–2.28)	1.43 (0.82–2.50)
91–180	1.17 (0.75–1.81)	1.24 (0.66–2.31)
181–365	1.33 (0.93–1.90)	0.97 (0.60–1.57)
Simvastatin vs atorvastatin (ref)
Overall	1.62 (1.50–1.75)	1.33 (1.16–1.53)
Time-specific* (days of follow-up)
1–30	1.86 (1.55–2.24)	1.91 (1.29–2.81)
31–90	1.65 (1.43–1.91)	1.46 (1.13–1.88)
91–180	1.57 (1.36–1.82)	1.31 (1.00–1.71)
181–365	1.51 (1.32–1.73)	1.09 (0.86–1.38)

CI confidence interval, PS propensity score, Ref reference

*Patients whose follow-up ended before the time window of interest were excluded from the respective analysis. We censored patients on the day of the end of the time window of interest in any given analysis